Development of simultaneous detection of total prostate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 1, 2011, Pages 37-42

  Xie, Chong ^a   Wang, Guomin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Luminex assay; Prostate cancer; Prostate specific antigen; Simultaneous detection; Tumor marker

Indexed keywords

BIOCHEMICAL MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5G6; MONOCLONAL ANTIBODY 8A6; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TECHNOLOGY;

ANTIBODIES, MONOCLONAL; EARLY DETECTION OF CANCER; FLUOROIMMUNOASSAY; HUMANS; LIMIT OF DETECTION; MALE; MICROSPHERES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78751492829     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20427     Document Type: Article

References (21)

1. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-2491.
2. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol 2000;38:380-387.
3. Björk T, Lilja H, Christensson A. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. BJU Int 1999;84:1021-1027.
4. Kilpeläinen TP, Tammela TL, Määttänen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer 2010;102:469-474.
5. Okamura K, Takaba H, Kamihira O, et al. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy. Int J Urol 2005;12:346-352.
6. Börgermann C, Swoboda A, Luboldt HJ, vom Dorp F, Rübben H. The f/t-PSA ratio in diagnosis of in-patients and out-patients: A unitary cutoff value is not useful. World J Urol 2009;27:581-585.
7. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-1791.
8. Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0ng/ml range of total PSA. BJU Int 2004;94:47-50.
9. Veltri RW, Miller MC. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology 1999;53:736-745.
10. Kuriyama M, Uno H, Ueno K, Hamamoto Y, Vihn PQ, Ban Y. Comparative study of assays for prostate-specific antigen molecular forms. Jpn J Clin Oncol 1999;29:303-307.
11. Hsu HY, Joos TO, Koga H. Multiplex microsphere-based flow cytometric platforms for protein analysis and their application in clinical proteomics-from assays to results. Electrophoresis 2009;30:4008-4019.
12. Wan XS, Xu YA, Ware JH, Kennedy AR. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex. Prostate 2003;56:131-141.
13. Chen Z, Chen H, Stamey TA. Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin. J Urol 1998;160:870-875.
14. Escamilla-Gómez V, Hernández-Santos D, González-García MB, Pingarrón-Carrazón JM, Costa-García A. Simultaneous detection of free and total prostate specific antigen on a screen-printed electrochemical dual sensor. Biosens Bioelectron 2009;24:2678-2683.
15. Okegawa T, Kinjo M, Watanabe K, et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0ng/ml. BJU Int 2000;85:708-714.
16. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology 2001;57:1105-1111.
17. Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 2006;76:27-30.
18. Lee YM, Jeong Y, Kang HJ, Chung SJ, Chung BH. Cascade enzyme-linked immunosorbent assay (CELISA). Biosens Bioelectron 2009;25:332-337.
19. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009;70:496-501. Epub April 11, 2009.
20. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006;309:200-204.
21. Kosmoliaptsis V, O'Rourke C, Bradley JA, Taylor CJ. Improved Luminex-based human leukocyte antigen-specific antibody screening using dithiothreitol-treated sera. Hum Immunol 2010;71:45-49.